Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
CRT
Chemoradiotherapy
SOX
oxaliplatin
rectal cancer
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
25
10
2020
revised:
10
11
2020
accepted:
11
11
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
To evaluate the benefits of the addition of oxaliplatin (OX) to fluoropyrimidine (FP)-based neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancers (LARCs). We performed retrospective analyses comparing the pathological complete response (pCR) rate, overall survival (OS), recurrence-free survival (RFS), and local recurrence-free survival (LRFS) between FP-based and FP+OX-based CRT groups and for patients who had completed the CRT. One hundred patients were included in the analyses: the pCR rate, OS, RFS, and LRFS were similar between these groups. The FP+OX group showed significantly more frequent incompleteness of the CRT compared to the FP group (p=0.049). Among the patients who had completed the CRT, the FP+OX group demonstrated significantly improved LRFS compared to the FP group (p=0.048). The addition of OX to an FP regimen in neoadjuvant CRT for LARC may reduce local recurrence in patients who have achieved good compliance to CRT.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
To evaluate the benefits of the addition of oxaliplatin (OX) to fluoropyrimidine (FP)-based neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancers (LARCs).
PATIENTS AND METHODS
METHODS
We performed retrospective analyses comparing the pathological complete response (pCR) rate, overall survival (OS), recurrence-free survival (RFS), and local recurrence-free survival (LRFS) between FP-based and FP+OX-based CRT groups and for patients who had completed the CRT.
RESULTS
RESULTS
One hundred patients were included in the analyses: the pCR rate, OS, RFS, and LRFS were similar between these groups. The FP+OX group showed significantly more frequent incompleteness of the CRT compared to the FP group (p=0.049). Among the patients who had completed the CRT, the FP+OX group demonstrated significantly improved LRFS compared to the FP group (p=0.048).
CONCLUSION
CONCLUSIONS
The addition of OX to an FP regimen in neoadjuvant CRT for LARC may reduce local recurrence in patients who have achieved good compliance to CRT.
Identifiants
pubmed: 33402514
pii: 35/1/593
doi: 10.21873/invivo.12296
pmc: PMC7880724
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
593-601Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Crit Rev Oncol Hematol. 2011 Sep;79(3):224-50
pubmed: 20719530
J Natl Cancer Inst. 2015 Sep 14;107(11):
pubmed: 26374429
J Anus Rectum Colon. 2018 May 25;1(3):65-73
pubmed: 31583303
Am J Surg. 2007 Oct;194(4):542-8
pubmed: 17826076
In Vivo. 2020 Nov-Dec;34(6):3559-3564
pubmed: 33144468
Anticancer Res. 2020 Feb;40(2):865-871
pubmed: 32014930
J Natl Compr Canc Netw. 2013 Mar 1;11(3):298-307; quiz 307
pubmed: 23486456
Radiother Oncol. 2015 Aug;116(2):209-13
pubmed: 26337743
J Clin Oncol. 2012 Dec 20;30(36):4558-65
pubmed: 23109696
Clin Colorectal Cancer. 2018 Sep;17(3):240-246
pubmed: 29934092
Radiat Oncol. 2015 Jan 23;10:24
pubmed: 25612635
Ann Oncol. 2017 Oct 1;28(10):2436-2442
pubmed: 28961836
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
J Clin Oncol. 2016 Sep 20;34(27):3300-7
pubmed: 27480145
Int J Clin Oncol. 2020 Jan;25(1):1-42
pubmed: 31203527
JAMA Surg. 2017 Jun 1;152(6):558-564
pubmed: 28273303
JAMA Oncol. 2020 Sep 1;6(9):1416-1421
pubmed: 32644104
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Support Care Cancer. 2020 Oct;28(10):4781-4788
pubmed: 31974772
Br J Cancer. 2017 Oct 24;117(9):1286-1294
pubmed: 28859058
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD002102
pubmed: 17443515
Radiother Oncol. 2019 May;134:199-203
pubmed: 31005216
J Clin Oncol. 2011 Jul 10;29(20):2773-80
pubmed: 21606427